About Arij

This author has not yet filled in any details.
So far Arij has created 23 blog entries.

Recording of M4K Pharma’s Scientific Update Meeting – June 12th, 2019

By | 2019-06-14T13:28:12+00:00 June 14th, 2019|

Listen to a recording of the June 2019 Monthly Scientific Meeting Listen to M4K Pharma's Scientific Update Meeting from June 12th, 2019 where our scientists and collaborators discuss the latest progress in our Medicines4Kids project for a deadly children's brain cancer called DIPG. Everyone is invited to hear first-hand how we are [...]

Recording of M4K Pharma’s Scientific Update Meeting – May 8th, 2019

By | 2019-05-16T15:18:36+00:00 May 16th, 2019|

Listen to a recording of the May 2019 Scientific Update Meeting Listen to M4K Pharma's Scientific Update Meeting from May 8th, 2019 where our scientists and collaborators discuss the latest progress in our Medicines4Kids project for a deadly children's brain cancer called DIPG. Everyone is invited to hear first-hand how we are [...]

Study published on new drug class targeting ACVR1 mutation for DIPG

By | 2019-05-16T15:20:11+00:00 May 9th, 2019|

Study published on new drug class targeting ACVR1 mutation for DIPG Scientists at The Institute of Cancer Research, London, along with colleagues at the Structural Genomics Consortium in Oxford, have published their findings on a new drug class that can kill brain cancer cells with mutations in the ACVR1 gene and shrink tumours in mice. Mutated versions [...]

Recording of M4K Pharma’s Scientific Update Meeting – April 24th, 2019

By | 2019-05-16T15:09:52+00:00 April 29th, 2019|

Listen to a recording of the April 24th 2019 Scientific Update Meeting Listen to our scientists and collaborators discuss the latest progress in M4K Pharma’s quest for a medicine for DIPG- a deadly children’s brain cancer. Everyone is invited to dial-in and join our live meetings. To find out when our next [...]

Recording of M4K Pharma’s Scientific Update Meeting – April 10th, 2019

By | 2019-04-15T11:48:04+00:00 April 15th, 2019|

Recording of M4K Pharma’s Scientific Update Meeting – April 10th, 2019 Listen to our scientists and collaborators discuss the latest progress in M4K Pharma’s quest for a medicine for DIPG- a deadly children’s brain cancer. Everyone is invited to dial-in and join our live meetings. To find out when our next meeting [...]

Recording of M4K Pharma’s Scientific Update Meeting – March 6th, 2019

By | 2019-03-20T21:47:26+00:00 March 15th, 2019|

Recording of M4K Pharma’s Scientific Update Meeting – March 6th, 2019 Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer. Everyone is invited to dial-in and join our live meetings. To find out when our next meeting will be, follow [...]

M4ND Pharma: Open science drug discovery model expands to neurodegenerative diseases

By | 2019-03-01T20:04:00+00:00 February 16th, 2019|

Medicines for Neurodegeneration (M4ND) Pharma launched! Following in the path of M4K Pharma, M4ND will tackle neurodegenerative diseases such as Parkinson’s disease, thanks to funding from the Krembil Foundation, and will commit to open science practises, open sharing of data, and affordable pricing. https://www.utoronto.ca/news/u-t-researcher-s-open-science-drug-discovery-model-expands-neurodegenerative-diseases  

For Innovation, Open Science Means Open for Business

By | 2019-05-31T11:20:26+00:00 February 7th, 2019|

Richard Gold (McGill University) and Max Morgan (SGC, M4k Pharma) penned an opinion piece in the Globe and Mail discussing how open science projects with no patents can result in local economic development, citing the recent $1Billion investment deal that Celgene signed with the Ontario Institute for Cancer Research (OICR) and their commercialization arm FACIT [...]

Recording of M4K Pharma’s Scientific Update Meeting – December 4th, 2018.

By | 2018-12-07T21:20:51+00:00 December 7th, 2018|

Recording of M4K Pharma's Scientific Update Meeting - December 4th, 2018 Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer. In this meeting, the team provides a comprehensive summary of the project accomplishments at the one year [...]